Introduction
============

The incidence of non-Hodgkin lymphoma (NHL) involving the Waldeyer's ring (WR) has been increasing in Asia \[[@b1-roj-2016-01781]\]. The WR includes the pharyngeal (adenoids), tubal, palatine and lingual tonsils (base of the tongue), and WR lymphoma most frequently occurs in the palatine tonsil \[[@b1-roj-2016-01781],[@b2-roj-2016-01781]\]. The location of disease is considered an important prognostic factor for primary extranodal lymphomas \[[@b3-roj-2016-01781]\]. Each of the WR subsites are considered to be independent prognostic factors, and the International Lymphoma Radiation Oncology Group recommends that it is not necessary to treat the entire WR in case of primary tonsillar lymphoma \[[@b4-roj-2016-01781]\]. The majority of reports on tonsillar lymphoma include all WR lymphoma cases; thus, it is difficult to define the treatment results, prognostic factors, and the optimum radiotherapy (RT) courses for primary tonsillar lymphoma \[[@b5-roj-2016-01781],[@b6-roj-2016-01781]\]. Furthermore, there is controversy regarding the prognosis of primary tonsillar lymphoma, which requires further evaluation.

Chemotherapy combined with RT is considered the standard treatment for limited-stage diffuse large B-cell lymphoma (DLBCL) since a report by the Southwest Oncology Group (SWOG) 8736 trial \[[@b7-roj-2016-01781]\]. Several studies have shown that RT prolongs progression-free survival (PFS) \[[@b8-roj-2016-01781],[@b9-roj-2016-01781]\]. However, in long-term follow-up studies involving the use of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), the role of RT requires clarification \[[@b10-roj-2016-01781]-[@b12-roj-2016-01781]\]. With regard to tonsillar lymphoma, a few studies have reported that higher radiation doses result in better local control and overall survival (OS). However, the therapeutic effects of RT and the optimal RT dose require further evaluation with respect to tonsillar lymphoma \[[@b2-roj-2016-01781],[@b13-roj-2016-01781],[@b14-roj-2016-01781]\].

We reviewed patients treated with chemotherapy combined with consolidative RT, and the prognosis and treatment outcomes were analyzed.

Materials and Methods
=====================

We retrospectively reviewed patients treated with chemotherapy combined with RT for primary tonsillar lymphoma between September 1993 and December 2014 at Seoul St. Mary\'s Hospital. A total of 19 patients were included in the study. Inclusion criteria were as follows: 1) the predominant location of the tumor was the palatine tonsil; 2) the tumor was pathologically confirmed as lymphoma; 3) histology was classified according to the World Health Organization classification, and diffuse large B cell lymphoma (DLBCL) was included; 4) the tumor was Ann Arbor stage I-III; 5) the tumor was treated with chemotherapy combined with RT; 6) the response to chemotherapy was complete or partial remission; 7) RT was prescribed for consolidative purposes; and 8) the patient was followed-up for at least 3 months after RT. Patients were classified according to the Ann Arbor staging system. To evaluate each patient's characteristics, including age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidity, presenting symptoms, B symptoms (fever, night sweats, and weight loss), initial lactate dehydrogenase (LDH) levels, international prognostic index (IPI) score, Ann Arbor stage, and histologic findings were reviewed. A tumor more than 5 cm in diameter was defined as bulky disease. Chemotherapy regimen, number of chemotherapy cycles, surgery type, RT dose, RT field, and RT technique were also examined.

PFS and OS were analyzed. PFS was calculated as the period from the first day of chemotherapy to the date of disease progression or death due to any cause. OS was calculated as the period from the first day of chemotherapy to the date of death due to any cause. PFS and OS were analyzed using the Kaplan-Meier method, and prognostic factors were compared using the log-rank test in univariate analysis. A p-value of \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS ver. 20 (IBM Co., Armonk, NY, USA). The acute and late toxicities related to RT were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0. This study was approved by the Institutional Review Board of Seoul St. Mary\'s Hospital.

Results
=======

1. Patients and treatment characteristics
-----------------------------------------

A total of 19 patients with primary tonsillar lymphoma were evaluated in this study. The patient characteristics and treatments administered are shown in [Table 1](#t1-roj-2016-01781){ref-type="table"}. The age of the patients ranged between 26 and 79 years, with a median of 51 years. The most common presenting symptoms were sore throat (57.9%) and neck mass (42.1%). Tonsillectomy for pathologic diagnosis was performed for 5 patients (26.3%). All patients received combined treatment with chemotherapy and RT. Chemotherapy was administered prior to RT. The chemotherapy regimens included cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in 6 patients (31.6%) and R-CHOP in 13 patients (68.4%). The median number of chemotherapy cycles was 6 (range, 1 to 8). The majority of patients (89.5%) showed complete remission after chemotherapy. RT was delivered using a megavoltage linear accelerator. The two-dimensional (2D) RT technique was used in 4 patients who had been treated before 1999. Eleven patients were treated with the three-dimensional (3D) RT technique, and 4 patients were treated with intensity-modulated radiotherapy (IMRT). Both the WR region and neck lymph nodes (LNs) were included in the RT field. RT was administered to the WR region or tonsillar area with a median dose of 36 Gy (range, 30 to 55.8 Gy) per 1.8--2 Gy fraction size, and to neck lymph nodes with a median of 30.6 Gy (range, 26 to 50.4 Gy) per 1.5--2 Gy fraction size. [Fig. 1](#f1-roj-2016-01781){ref-type="fig"} displays the IMRT planning for 1 patient who had complete remission after receiving R-CHOP chemotherapy for the treatment of Ann Arbor stage II tonsillar lymphoma.

2. Treatment outcome
--------------------

After a median follow-up of 53 months (range, 7 to 249 months), there was no evidence of disease in any of the 15 survivors. Three incidences of recurrence were observed during the follow-up; 2 patients had regional (neck LN) failure, and the remaining patient had distant failure in the abdominalpelvic LN and vagina. The regional failure sites had previously been included in the RT field. The 5-year locoregional control rate was 88.1%. Univariate analysis was not performed because of the small number of cases of locoregional recurrences.

The 5-year PFS and OS rates were 74.6% and 80% ([Fig. 2A](#f2-roj-2016-01781){ref-type="fig"} and [B](#f2-roj-2016-01781){ref-type="fig"}). Univariate analysis was performed for PFS and OS ([Table 2](#t2-roj-2016-01781){ref-type="table"}). The R-CHOP regimen generally resulted in a better PFS than the CHOP regimen (88.9% vs. 50.0%; p = 0.053). RT dose was related to the survival outcome (p = 0.010 for PFS and p = 0.044 for OS). Other factors, including sex, age, comorbidities, initial LDH level, ECOG performance status, and RT technique, had no influence on PFS and OS. The majority of patients had Ann Arbor stage II disease (78.9%) and an IPI score of 0 (89.5%), which were not included in the univariate analysis. Multivariate analysis was not conducted because of the small number of patients included. One patient received one cycle of R-CHOP chemotherapy due to poor general condition, and RT was prescribed at a dose of \>40 Gy. Once the aforementioned patient had been excluded, the patients who were treated with the CHOP regimen received a higher RT dose (median, 50.4 Gy) than those treated with the R-CHOP regimen (median, 33.3 Gy). The patients treated with the CHOP regimen followed by RT were treated between 1993 and 2001, and patients in the R-CHOP + RT group were treated between 2009 and 2015. Subsequent to the adjustment in treatment strategy, the patients were classified into two groups: CHOP + RT (\>40 Gy) group and R-CHOP + RT (≤40 Gy) group. The 5-year PFS rates were 50% in the CHOP + RT group and 100% in the R-CHOP + RT group (p = 0.018), as shown [Fig. 2C](#f2-roj-2016-01781){ref-type="fig"}, and the 5-year OS rates were 66.7% and 100%, respectively (p = 0.087), as shown [Fig. 2D](#f2-roj-2016-01781){ref-type="fig"}.

Most patients showed a mild degree of acute oropharyngeal mucositis and xerostomia during treatment with RT. Of the CHOP + RT patients, 5 patients (83.3%) experienced grade 2 oropharyngeal mucositis and 2 patients (33.3%) had grade 2 xerostomia. Grade 2 mucositis and xerostomia developed in 5 patients (38.5%) and 3 patients (23.1%), respectively, in the R-CHOP + RT group. There was no difference of acute toxicity rate between the two groups. Grade 2 xerostomia persisted in 1 patient (16.7%) and 2 patients (15.4%) in the CHOP + RT and the R-CHOP + RT groups, respectively. There were no grade 3 or higher toxicities associated with RT. Hypothyroidism was observed in 1 patient in the CHOP + RT group at 29 months after RT. One patient developed a second malignancy (Kaposi's sarcoma) in the left base of the tongue (previous radiation field) at 39 months after RT. The patient was treated with 1 cycle of R-CHOP chemotherapy and then RT (45 Gy/25 fraction) on the left tonsillar lesion and left neck node for tonsillar lymphoma. The patient died 1.5 months after the diagnosis of the second malignancy.

Discussion and Conclusion
=========================

In this study, we evaluated the treatment outcomes of patients with primary tonsillar lymphoma who were treated with chemotherapy in combination with RT. The majority of patients presented with early-stage disease. After a relatively long-term follow up, our patients showed a 5-year PFS rate of 74.6% and a 5-year OS rate of 80%, which is comparable to the results of previous reports (61% and 67%, respectively) \[[@b15-roj-2016-01781]\]. R-CHOP combined with low-dose consolidative RT resulted in a better treatment outcome than CHOP combined with high-dose consolidative RT.

Chemotherapy combined with RT has been considered the standard treatment for limited-stage NHL since the SWOG 8736 study. Although there is controversy regarding the consolidative role of RT, several studies have shown that the addition of RT to chemotherapy improves PFS for patients with NHL \[[@b7-roj-2016-01781]-[@b9-roj-2016-01781],[@b11-roj-2016-01781]\]. Laskar et al. \[[@b13-roj-2016-01781]\] demonstrated that disease-free survival (DFS) and OS rates are higher in patients treated with chemotherapy combined with RT than in those treated with chemotherapy alone. Mohammadianpanah et al. \[[@b15-roj-2016-01781]\] also reported a significantly better DFS rate by using a combined treatment involving chemotherapy and RT, which is consistent with our study.

It has been documented that R-CHOP improves PFS and OS without significant toxic effects \[[@b16-roj-2016-01781]\]. Thus, R-CHOP chemotherapy has been established as the standard treatment for aggressive NHL. Although the role of RT in R-CHOP chemotherapy has been reevaluated, there is no convincing evidence for the necessity of a higher RT dose \[[@b11-roj-2016-01781],[@b12-roj-2016-01781]\]. Phan et al. \[[@b12-roj-2016-01781]\] reviewed 44 DLBCL patients treated with R-CHOP, with or without consolidative RT (30--39.6 Gy), after 6 to 8 cycles of R-CHOP using matched pair analysis. With lower RT doses than those of previous studies, such as SWOG 8736, SWOG 0014, and ECOG 1484, R-CHOP chemotherapy with RT significantly improved the 5-year PFS and OS rates compared to chemotherapy alone. However, to the best of our knowledge, there have been no reports on the role of RT in R-CHOP chemotherapy for tonsillar lymphoma. In our study, we evaluated patients with DLBCL who were treated with R-CHOP (median, 6 cycles) and low-dose consolidative RT (median, 33.3 Gy), who demonstrated 5-year PFS and OS rates of 100% without experiencing significant toxicity. It is suggested that RT may serve a role in R-CHOP chemotherapy era of primary tonsillar lymphoma.

Laskar et al. \[[@b13-roj-2016-01781]\] suggested that a higher RT doses results in significantly better survival in tonsillar lymphoma. The DFS (91% vs. 59.7%, p = 0.039) and OS (88.2% vs. 78.9%, p = 0.014) rates were found to be significantly higher in patients who were irradiated with ≥45 Gy. In multivariate analysis, a radiation dose of \<45 Gy was significantly related to a lower DFS and OS rate \[hazard ratio (HR) 9.65, p = 0.005 and HR 9.89, p = 0.007\]. Mohammadianpanah et al. \[[@b14-roj-2016-01781]\] reported that the 5-year cause-specific and relapse-free survival rates were both 100% in patients with tonsillar lymphoma who were irradiated with 40--50 Gy. However, these studies have certain limitations in terms of interpreting the results because the majority of patients included were treated with CHOP chemotherapy. There have been attempts toward decreasing RT doses because of the RT-related toxicities reported in numerous studies. Lowry et al. \[[@b17-roj-2016-01781]\] reported that there was no significant difference in local control, PFS, or OS between low-dose (30 Gy) and high-dose (40--45 Gy) RT in NHL. In our study, patients treated with R-CHOP chemotherapy combined with low-dose (median, 33.3 Gy) RT showed good survival rates. Both of the 5-year PFS and OS rates were 100%. Therefore, RT doses need to be modified in patients receiving chemotherapy regiments with rituximab, as suggested by Phan et al. \[[@b12-roj-2016-01781]\].

Previous studies have indicated that disease stage, IPI score, disease bulkiness, B symptoms, and performance status are prognostic factors for PFS, DFS, or OS \[[@b13-roj-2016-01781],[@b15-roj-2016-01781]\]. The majority of our patients had early-stage disease, an IPI score of 0, no bulky disease, no B symptoms, and a good performance status. Therefore, there was no significant difference in PFS or OS according to these clinical factors. Another limitation of our study was the small number of patients included and the relatively short follow-up period of the R-CHOP chemotherapy group.

In conclusion, the results of this study suggest that chemotherapy (R-CHOP) combined with relatively low-dose consolidative RT may be a safe and effective treatment for primary tonsillar lymphoma. Despite controversy regarding prognosis, patients with primary tonsillar lymphoma generally have favorable outcomes; therefore, high-dose RT is not necessary to improve local control and survival.
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![Intensity-modulated radiotherapy for the primary tonsillar lymphoma. A 37-year-old man presented with a right neck mass. (A) Initial neck computed tomography scan shows multiple lymph node enlargements in the right neck level II. Diffuse large B-cell lymphoma was confirmed by excisional biopsy. (B) High fludeoxyglucose uptake is noted in the right palatine tonsil (SUVmax, 22.8), and postoperative changes are seen in the right neck on positron emission tomography, which confirm a diagnosis of Ann Arbor stage II tonsillar lymphoma. (C) He was treated with 6 cycles of R-CHOP chemotherapy and had complete remission. (D) Consolidative radiotherapy was delivered to the primary tonsillar lesion (red line) with 36 Gy/20 fractions for 4 weeks (orange color) and to the right neck lymph nodes (blue line) with 30 Gy/20 fractions for 4 weeks (light blue color). SUVmax, maximum standardized uptake value; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.](roj-2016-01781f1){#f1-roj-2016-01781}

![(A) Progression-free survival (PFS) and (B) overall survival (OS) rates for all patients, and according to the treatment type, CHOP + RT group and R-CHOP + RT group (C, D). CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RT, radiotherapy.](roj-2016-01781f2){#f2-roj-2016-01781}

###### 

Patient and treatment characteristics

  Characteristic            Value
  ------------------------- ----------------
  Sex                       
   Male                     12 (63.2)
   Female                   7 (36.8)
  Age (yr)                  51 (26-79)
  ECOG performance status   
   0                        9 (47.4)
   1                        10 (52.6)
  Comorbidity               
   Yes                      6 (31.6)
   No                       13 (68.4)
  Ann Arbor stage           
   I                        3 (15.8)
   II                       15 (78.9)
   III                      1 (5.3)
  B symptom                 
   No                       19 (100)
   Yes                      0 (0)
  Initial LDH               
   Normal                   13 (68.4)
   Elevated                 5 (26.3)
   Unknown                  1 (5.3)
  IPI                       
   0                        17 (89.5)
   1                        1 (5.3)
   2                        1 (5.3)
  Chemotherapy regimen      
   CHOP                     6 (31.6)
   R-CHOP                   13 (68.4)
  Chemotherapy response     
   Complete remission       17 (89.5)
   Partial remission        2 (10.5)
  RT technique              
   2D                       4 (21.1)
   3D                       11 (57.9)
   IMRT                     4 (21.1)
  RT dose, tonsil (Gy)      36 (30-55.8)
   \>40                     7 (36.8)
   ≤40                      12 (63.2)
  RT dose, neck (Gy)        30.6 (26-50.4)
   \>40                     7 (36.8)
   ≤40                      12 (63.2)

Values are presented as number of patients (%) or median (range). ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, international prognostic index; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RT, radiotherapy; 2D, two-dimensional; 3D, three-dimensional; IMRT, intensity-modulated radiotherapy.

###### 

Univariate analysis or prognostic factor of survival outcome

  Characteristic            No. of patients   5-yr PFS (%)   p-value   5-yr OS (%)   p-value
  ------------------------- ----------------- -------------- --------- ------------- ---------
  Sex                                                        0.735                   0.620
   Male                     12                76.2                     75            
   Female                   7                 71.4                     85.7          
  Age (yr)                                                   0.885                   0.399
   \<50                     8                 72.9                     71.4          
   ≥50                      11                77.1                     87.5          
  ECOG performance status                                    0.054                   0.132
   0                        9                 100                      100           
   1                        10                55.6                     66.7          
  Comorbidity                                                0.264                   0.604
   Yes                      6                 53.3                     75            
   No                       13                81.8                     81.8          
  Initial LDH                                                0.315                   0.600
   Normal                   13                77.8                     77.8          
   Elevated                 5                 60                       80.0          
  Chemotherapy regimen                                       0.053                   0.258
   CHOP                     6                 50.0                     66.7          
   R-CHOP                   13                88.9                     88.9          
  RT technique                                               0.143                   0.538
   2D                       4                 50.0                     75.0          
   3D + IMRT                15                82.5                     81.8          
  RT dose (Gy)                                               0.010                   0.044
   \>40                     7                 42.9                     57.1          
   ≤40                      12                100                      100           

PFS, progression free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RT, radiotherapy; 2D, two-dimensional; 3D, three-dimensional; IMRT, intensity-modulated radiotherapy.
